Surgical Ventricular Restoration

Policy Number: 7.01.103        Last Review: 9/2014

Policy
Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide coverage for Surgical Ventricular Restoration. This is considered investigational.

When Policy Topic is covered
Not Applicable

When Policy Topic is not covered
Surgical ventricular restoration is considered investigational for the treatment of ischemic dilated cardiomyopathy or post-infarction left ventricular aneurysm.

Considerations
Surgical ventricular restoration involves increased physician work compared to standard ventriculectomy. For example, the procedure includes evaluation of the ventricular septum and reshaping of the geometry of the heart. Surgical ventricular restoration is described as a global treatment of left ventricular failure, while conventional left ventricular aneurysmectomy represents a local treatment of a transmural infarct.

Description of Procedure or Service
Surgical ventricular restoration (SVR) is a procedure designed to restore or remodel the left ventricle to its normal, spherical shape and size in patients with akinetic segments of the heart, secondary to either dilated cardiomyopathy or post-infarction left ventricular aneurysm.

Background
The surgical ventricular restoration (SVR) procedure may also be referred to as ventricular remodeling, surgical anterior ventricular endocardial restoration (SAVER), left ventricular reconstructive surgery, left ventricular aneurysmectomy reconstruction, endoventricular circular plasty, or the Dor procedure after Vincent Dor, MD. Dr. Dor pioneered the expansion of techniques for ventricular reconstruction and is credited with treating heart failure patients with SVR in conjunction with coronary artery bypass grafting (CABG).

The SVR procedure is usually performed after CABG and may proceed or be followed by mitral valve repair or replacement and other procedures such as endocarctectomy and cryoablation for treatment of ventricular tachycardia. A key difference between SVR and ventriculectomy (i.e., for aneurysm removal) is that in SVR circular “purse string” suturing is used around the border of the aneurysmal scar tissue. Tightening of this suture is believed to isolate the akinetic or dyskinetic scar, bring the healthy portion of the ventricular walls together, and restore a more normal ventricular contour. If the defect is large (i.e., an opening >3 cm), the ventricle may also be reconstructed using patches of autologous or artificial material to maintain the desired ventricular volume and contour during closure of the ventriculotomy. In addition, SVR is distinct from partial left ventriculectomy (i.e., the Batista procedure, see separate policy), which does not attempt to specifically resect akinetic segments and restore ventricular contour.
Regulatory Status
The CorRestore™ Patch System is a device approved by the U.S. Food and Drug Administration (FDA) through the 510(k) process that is specifically labeled for use “as an intracardiac patch for cardiac reconstruction and repair.” The device consists of an oval tissue patch made from glutaraldehyde-fixed bovine pericardium. It is identical to other marketed bovine pericardial patches except that it incorporates an integral suture bolster in the shape of a ring that is used along with ventricular sizing devices to restore the normal ventricular contour.

Rationale
This policy was originally created in 2005 and was regularly updated with searches of the MEDLINE database. The most recent literature search was performed for the period of June 2012 through June 2013. Following is a summary of the key literature to date with a focus on controlled trials:

At the time this policy was created, a review of the peer-reviewed literature on MEDLINE revealed many publications on a variety of approaches to surgical ventricular restoration (SVR). These publications primarily consisted of case series reports and retrospective reviews from single centers, with the exception of publications from the multicenter Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the Left Ventricle (RESTORE) Group. The RESTORE Group is an international group of cardiologists and surgeons from 13 centers that had investigated SVR for the past 20 years in more than 1,000 patients with ischemic cardiomyopathy following anterior infarction. (1-6) While the SVR procedure had been performed for many years, the available data were inadequate to permit conclusions regarding health benefits associated with SVR. Specifically, the lack of any randomized controlled trials (RCTs) comparing SVR to other surgical or medical therapies did not permit scientific assessment of the efficacy of SVR. In addition, patient selection criteria and optimal surgical techniques were still undetermined.

In 2002, a randomized, multicenter international clinical trial on the Surgical Treatment of Ischemic Heart Failure (STICH) was initiated to compare medical therapy with coronary artery bypass grafting (CABG) and/or SVR for patients with heart failure and coronary heart disease (ClinicalTrials.gov Identifier: NCT00023595). The STICH trial was sponsored by the National Heart, Lung, and Blood Institute and was expected to recruit 2,800 patients with heart failure, left ventricular ejection fraction <0.35, and coronary artery disease amenable to CABG at 50 clinical sites. Patients with extensive anterior ischemia assigned to the surgical arm of the study were to be further randomized to CABG surgery alone versus bypass surgery plus SVR. The 2009 results of this trial, as well as a representative sample of some of the earlier case series on SVR, are discussed below.

Controlled Trials
In 2006, Ribeiro and colleagues from Brazil reported on 137 patients with anterior myocardial infarction (MI) and ejection fraction less than 50%. (7) Those patients who had viable anterior myocardium were randomized to SVR or SVR plus revascularization, and those patients with nonviable anterior myocardium received SVR. Ejection fraction improved in all groups, but the most improvement was in the SVR plus revascularization group.

Results of the National Heart, Lung, and Blood Institute-sponsored STICH trial were published in 2009. (8) This study was a multicenter, unblinded RCT performed at 127 clinical sites from 26 countries. A total of 1,000 patients with coronary artery disease and ejection fraction of 35% or less were randomized to CABG alone (n=499) or CABG plus SVR (n=501). The primary outcome was a composite of death from any cause and hospitalization for cardiac reasons. While SVR reduced the end-systolic volume index by 19% compared to 6% with CABG alone, there was no difference between groups in the primary outcome, which occurred in 292/499 (59%) of the CABG alone group compared to 289/501 (58%) of the CABG + SVR group (hazard ratio [HR]: 0.99, 95% confidence interval [CI]: 0.84-1.17, p=0.90). Death from any cause occurred in 141/499 (28%) in the CABG alone group compared to 138/501 (28%) in the CABG + SVR group (HR: 1.00, 95% CI: 0.79-1.26, p=0.98). Cardiac symptoms and exercise tolerance also improved to similar degrees between groups. Other secondary
outcomes, such as stroke, MI, and subsequent procedures, also did not differ between groups. Subgroup analysis did not reveal any patient groups that benefited from SVR significantly more than the entire group.

STICH investigators have subsequently conducted additional analyses in attempts to identify patient groups that might have improved outcomes with CABG and SVR over CABG alone. (9, 10) Subgroup analyses reported a trend suggesting patients with better preoperative left ventricular function, using measures such as left-ventricular ejection fraction (LVEF), end-systolic volume index and/or end-diastolic volume index might benefit from SVR, but subgroup differences did not reach statistical significance. For example, in the subgroup of patients with an LVEF of 33% or higher, the hazard ratio for the primary outcome was 0.77 (95% CI: 0.55-1.08), while in patients with an LVEF of 25% or less, the hazard ratio was 1.42 (95% CI: 1.02-1.98). Since these subgroup analyses were performed post-hoc and no statistically significant differences were reported, the results are inconclusive.

A separate publication from the STICH trial reported on quality-of-life (QOL) outcomes. (11) The main QOL outcome measure used was the Kansas City Cardiomyopathy Questionnaire (KCCQ), which is a 23-item scale meant to measure the effect of heart failure symptoms on QOL. Secondary QOL measures included the Seattle Angina Questionnaire, the short form (SF)-12, the CES-D depression measure, the Cardiac Self-Efficacy Questionnaire, and the EuroQoL 5-D. The questionnaires were administered at baseline and 4, 12, 24, and 36 months post-randomization. Available numbers of patients at each time point were 991, 897, 828, 751, and 669, respectively. Scores on the KCCQ QOL measures improved for both groups to a similar degree; there was no incremental benefit for the SVR group compared to the CABG alone group. Similarly, there were no group differences noted on any of the secondary QOL measures.

A second RCT was published in 2011 by Marchenko et al. (12) This was a study performed in Russia of 236 patients with ischemic heart failure who were randomized to CABG alone or CABG + SVR. The mean follow-up was 31±13 months. Outcome measures reported were perioperative mortality and survival at 1-, 2-, and 3-year follow-up. Perioperative mortality was 5.8% in the CABG alone group compared with 3.5% in the CABG + SVR group (p=NS, statistical tests not reported). Survival at 1 and 3 years was 95% and 78%, respectively, in the CABG + SVR group, compared with 83% and 78%, respectively, in the CABG alone group (statistical tests not reported). There were reductions in New York Heart Association (NYHA) functional class and angina class for both groups after surgery, but between-group statistical testing was not reported. For example, the NYHA functional class decreased in the CABG + SVR from 3.1±0.4 at baseline to 2.2±0.6 at 3 years, compared with a decrease in the CABG alone group from 2.9±0.5 to 2.4±0.9.

Uncontrolled Studies

Athanasuleas and colleagues from the RESTORE Group, reported on early and 3-year outcomes in 662 patients who underwent SVR following anterior MI during the period of January 1998 to July 2000. (5) In addition to SVR, patients also concomitantly underwent CABG (92%), mitral repair (22%), and mitral replacement (3%). The authors reported overall mortality during hospitalization was 7.7%; postoperative ejection fractions increased from 29.7% ± 11.3% to 40.0% ± 12.3% (p<0.05). The survival rate and freedom from hospitalization for heart failure at 3 years was 89.4% ± 1.3% and 88.7%, respectively. In a separate publication on 439 patients from the RESTORE Group, Athanasuleas and coworkers reported outcomes improved in patients with lower patient age, higher ejection fractions, and lack of need for mitral valve replacement. (6)

Mickleborough and colleagues reported on 285 patients who underwent SVR by a single surgeon for class III or IV heart failure, angina, or ventricular tachyarrhythmia during the period of 1983 to 2002. (13) In addition to SVR, patients also concomitantly underwent CABG (93%), patch septoplasty (22%), arrhythmia ablation (41%), mitral repair (3%), and mitral replacement (3%). SVR was performed on the beating heart in 7% of patients. The authors reported hospital mortality of 2.8%; postoperative ejection fractions increased 10% ± 9% from 24% ± 11% (p<0.000), and symptom class in 140 patients
improved 1.3 ± 1.1 functional class per patient. Patients were followed for up to 19 years (mean, 63 ± 48 months), and overall actuarial survival was reported as 92%, 82%, and 62% at 1, 5, and 10 years, respectively. The authors suggested wall-thinning should be used as a criterion for patient selection.

Bolooki and colleagues reported on 157 patients who underwent SVR by a single surgeon for class III or IV heart failure, angina, ventricular tachyarrhythmia, or MI using 3 operative methods during the period of 1979 to 2000. (14) SVR procedures consisted of radical aneurysm resection and linear closure (n=65), septal dyskinesis reinforced with patch septoplasty (n=70), or ventriculotomy closure with an intracavitary oval patch (n=22). The authors reported hospital mortality of 16%. The mean preoperative ejection fraction was 28% ± 0.9%. Patients were followed up for up to 22 years, and overall actuarial survival was reported as 53%, 30%, and 18% at 5, 10, and 15 years, respectively. The authors found factors improving long-term survival included SVR with intraventricular patch repair and ejection fraction of 26% or greater preoperatively.

Sartipy and colleagues reported on 101 patients who underwent SVR using the Dor procedure at a single center for class III or IV heart failure, angina, and ventricular tachyarrhythmia during the period of 1994 to 2004. (15) In addition to SVR, patients also concomitantly underwent CAGB (98%), arrhythmia ablation (52%), and mitral valve procedure (29%). The authors reported early mortality (within 30 days of operation) was 7.9%; left ventricular ejection fraction increased from 27% ± 9.9% to 33% ± 9.3% postoperatively. Patients were followed up 4.4 ± 2.8 years, and overall actuarial survival was reported as 88%, 79%, and 65% at 1, 3, and 5 years, respectively.

In 2006, Hernandez et al. reported on the contemporary performance of SVR based on data from the Society of Thoracic Surgeons’ (STS) database. (16) From January 2002 to June 2004, 731 patients underwent procedures at 141 hospitals. The operative mortality was 9.3%; combined death or major complications occurred in 33.5%. The authors commented that further studies of SVR are needed to improve patient selection and procedural performance. Tulner et al. reported on 6-month follow-up on 21 patients with ischemic dilated cardiomyopathy who underwent SVR and bypass grafting; some also had valve annuloplasty. (17) Improvement in a number of clinical variables was noted, including decreased left-ventricular dyssynchrony, reduced tricuspid regurgitation, and improved ejection fraction (27–36%).

Searches of the MEDLINE database have found that the published studies continue to primarily report on case series. In many, SVR was performed in conjunction with additional cardiac procedures. For example, Tulner et al. reported on 6-month outcomes on 33 patients with class III/IV heart failure who underwent SVR and/or restrictive mitral annuloplasty. (18) Operative mortality was 3%, and additional in-hospital mortality was 9%. Quality-of-life scores improved, as did 6-minute walking distance (248 to 422 meters). Williams et al. reported on a retrospective review of outcomes following SVR in a series of 34 patients with New York Heart Association (NYHA) class IV heart failure and 44 patients with class II/III who had surgery between January 2002 and December 2005. (19) There were 3 operative deaths in each group. While there was symptomatic improvement in both groups, there was a trend toward reduced survival at 32 months in those with class IV versus class II/III disease (68% vs. 88%, respectively). A non-randomized comparative study from Europe involving patients with coronary artery disease who underwent CABG or CABG plus SVR and had an ejection fraction of 30% to 40% was published in 2009. (20) In this non-randomized study, the authors concluded that patients in whom SVR was possible experienced more perioperative complications but had improved early and midterm outcomes. While these and similar studies show that some clinical improvement occurs following this surgery, the non-randomized nature of these studies limits the ability to draw conclusions. Controlled trials are needed to compare the outcomes of SVR to other alternatives.

**Ongoing Clinical Trials**

A search of online site ClinicalTrials.gov in July 2013 found one active Phase III trial on surgical ventricular restoration. The Surgical Treatment of Ischemic Heart Failure (STICH) study is a randomized, multicenter, international, clinical trial to compare medical therapy with coronary artery
bypass grafting (CABG) and/or SVR for patients with heart failure and coronary heart disease (NCT00023595). Although this trial is listed as ongoing, it is no longer recruiting patients and the main results of the CABG alone versus CABG plus surgical ventricular restoration have already been published and are reviewed in this reference policy.

**Summary**

Surgical ventricular restoration (SVR) is a procedure designed to restore or remodel the left ventricle to its normal, spherical shape and size in patients with akinetic segments of the heart, secondary to either dilated cardiomyopathy or post-infarction left ventricular aneurysm. A number of uncontrolled studies have suggested that surgical ventricular restoration can improve the hemodynamic functioning in selected patients with ischemic cardiomyopathy. However, the pivotal RCT, the Surgical Treatment of Ischemic Heart Failure (STICH) trial, did not report any improvements in clinical outcomes or quality-of-life measures for patients undergoing SVR in addition to standard coronary artery bypass grafting (CABG) surgery. As a result of these data, the impact of SVR on net health outcome remains uncertain. Therefore, SVR is considered investigational.

**Practice Guidelines and Position Statements**

In 2010, a Task Force of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery developed guidelines on myocardial revascularization. (21) These guidelines consider SVR combined with CABG to be a surgical option for patients with ischemic heart failure and left ventricular ejection fraction 35% or less (based on opinion and evidence that is not well-established). The guidelines also recommend SVR with CABG only be performed in centers with a high level of surgical expertise.

**Medicare National Coverage**

There is no national coverage determination.

**References**


Billing Coding/Physician Documentation Information

33548 Surgical ventricular restoration procedure, includes prosthetic patch, when performed (e.g., ventricular remodeling, SVR, SAVER, DOR procedure)

Additional Policy Key Words

N/A

Policy Implementation/Update Information

3/1/06 New policy added to the Surgery section. Considered investigational.
9/1/06 No policy statement changes.
3/1/07 No policy statement changes.
9/1/07 No policy statement changes.
3/1/08 No policy statement changes.
9/1/08 No policy statement changes.
3/1/09 No policy statement changes.
9/1/09 No policy statement changes.
3/1/10 No policy statement changes.
9/1/10 No policy statement changes.
3/1/11 No policy statement changes.
9/1/11 No policy statement changes.
3/1/12 No policy statement changes.
9/1/12 No policy statement changes.
3/1/13 No policy statement changes.
State and Federal mandates and health plan contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. The medical policies contained herein are for informational purposes. The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents Blue KC and are solely responsible for diagnosis, treatment and medical advice. No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, photocopying, or otherwise, without permission from Blue KC.